Clinical Trials

A.M.IgA. is a clinical research study evaluating the safety and effectiveness of an investigational (not approved for clinical use) medication in adults with IgAN that is now enrolling participants. The investigational medication, placebo, and all study-related tests will be provided to participants during their study participation.

I CAN is a Phase 3, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of ravulizumab (ALXN1210) in adults with immunoglobulin A nephropathy (IgAN).

The APRICOT study is an open-label, single-arm, multicenter Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics, safety, and tolerability of iptacopan in pediatric patients aged 2 to under 18 years with primary immunoglobulin A nephropathy (IgAN).  The goal of the study is to see if iptacopan has an effect on how well your kidneys work by measuring the level of protein in your urine (proteinuria). The study is also planning to see if iptacopan is safe and well tolerated in patients with IgAN.

Have you been diagnosed with IgA nephropathy? The ASSIST study is a phase 2, randomized, placebo-controlled, cross-over study of atrasentan* in adults with IgA nephropathy (IgAN). The ASSIST study is a clinical trial that will test an investigational drug named atrasentan, which is being developed for the treatment of IgAN, …

The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study of zigakibart (BION-1301 / Novartis FUB523) in adults with IgA nephropathy (IgAN). The BEYOND study is a clinical trial that will test an investigational drug named zigakibart which is being developed for the treatment of IgAN. The goal of the study is to see if zigakibart has an effect on how well your kidneys work by measuring the level of protein in your urine (proteinuria) and how well your kidneys are filtering blood (estimated glomerular filtration rate also known as eGFR). The study is also planning to see if zigakibart is safe and well tolerated in patients with IgAN.

BHV1400-102 is an ongoing multi-center, 1-year, open-label study evaluating BHV-1400 as a potential treatment for IgA nephropathy. BHV-1400 was designed to selectively target and remove disease-causing Gd-IgA1 without removing normal immunoglobulins. All study participants will receive the study drug; there is no placebo arm. The purpose of the study is to assess thesafety and tolerability of BHV-1400 in people with immunoglobulin A nephropathy (IgAN) , to track the reduction of Gd-IgA1 and how this reduction impacts the measures of proteinuria and kidney function. In addition, the level of healthy antibodies (IgA, IgE, IgG and IgM) are monitored. All study-related tests will be provided to participants during their study participation, free of charge.

Travere Therapeutics is evaluating a study medication called sparsentan to determine if it will be a safe and effective treatment that helps slow the decline of kidney function in children living with rare kidney diseases.

The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ravulizumab IV in pediatric participants to support the extrapolation of efficacy from the adult population. Who is eligible: Children and adolescents ages 2 to less than 18 years of age at the …

 IMAGINATION is a phase 3, randomized, double-blind, placebo-controlled trial that aims to evaluate a novel therapy, Sefaxersen (RO7434656), in adults with IgA nephropathy to establish its effectiveness and safety in treating this condition.

Efficacy and safety of extended TARPEYO® (budesonide) delayed release capsules treatment beyond 9 months in adult patients The study assesses the efficacy and safety of extended TARPEYO® treatment in adult participants who have completed 9 months of TARPEYO 16 mg daily treatment. The study treatment period is 15 months; TARPEYO 16 mg daily dose will be taken for 6-months followed by 8 mg daily dose for 9-months.

The study will assess the safety and efficacy of atacicept in multiple autoimmune glomerular diseases including IgAN (IgA Nephropathy), pMN (Primary Membranous Nephropathy) and MCD/FSGS (Minimal Change Disease/Focal Segmental Glomerulosclerosis) in participants ages 10 and above with weekly SC injections.

PREVAIL is a study enrolling people around the world who have immunoglobulin A nephropathy, also known as IgAN. Kidney damage from IgAN can lead to protein and blood leaking into the urine (proteinuria). The main goal of PREVAIL is to learn about the effects of a study drug called felzartamab on proteinuria in adults with IgAN. Participants will be randomly assigned to receive either felzartamab or placebo for over 20 weeks.

The RAINIER Study: RAINIER is a phase 3 registrational, randomized, placebo-controlled study of povetacicept in adults with IgA Nephropathy (IgAN). The drug is administered once every 4 weeks as a subcutaneous injection. There is a 2 in 3 (67%) chance of receiving study drug and a 1 and 3 (33%) chance of receiving placebo (an inactive substance

VISIONARY: A Phase 3 clinical trial of sibeprenlimab for adults with IgA Nephropathy. Targeting a brighter future for IgAN patients.